Total reported value
$157.6M
Reporting period: 2026-03-31 · Number of holdings: 9
Sarissa Capital Management LP disclosed 9 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $157.6M and a quarterly turnover rate of 35.9%.
Trim NBIX
-61.6% -$27.6M
Add INVA
-24.3% -$6.6M
Add AMRN
0.0% $845.1K
Trim IRWD
-42.3% -$21.4M
Add LNTH
-8.0% $585.3K
Trim CYTK
-42.3% -$10.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INVA | Innoviva INC | Stock-Other | 31.50% | +6.25% | -24.33% | |
| 2 | IRWD | Ironwood Pharmaceuticals INC | Stock-Other | 20.46% | -3.61% | -42.28% | |
| 3 | AMRN | Amarin CORP PLC -adr | Stock-Other | 15.35% | +4.87% | — | |
| 4 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 9.74% | -9.55% | -61.56% | |
| 5 | CYTK | Cytokinetics INC | Stock-Healthcare | 9.56% | -1.74% | -42.32% | |
| 6 | LNTH | Lantheus Holdings INC | Stock-Healthcare | 8.03% | +2.61% | -8.01% | |
| 7 | BHVN | Biohaven Ltd. | Stock-Other | 3.02% | +0.42% | +9.74% | |
| 8 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.05% | +0.60% | — | |
| 9 | VOR | Vor Biopharma INC | Stock-Other | 0.29% | +0.14% | — |
Performance for Q3 2026
+12.2%
Performance Last 4 Quarters
+22.7%
Based on 80% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 9 | $157.6M | 36 | |
| 2025-12-31 | 9 | $222.9M | 29 | |
| 2025-09-30 | 8 | $180.4M | 33 | |
| 2025-06-30 | 7 | $154.4M | 0 | |
| 2025-03-31 | 7 | $154.7M | 100 | |
| 2024-12-31 | 8 | $322.9M | 0 | |
| 2024-09-30 | 10 | $402.3M | 0 | |
| 2024-06-30 | 10 | $592.4M | 0 | |
| 2024-03-31 | 10 | $571.6M | 0 | |
| 2023-12-31 | 9 | $648.9M | 0 | |
| 2023-09-30 | 11 | $742.4M | 0 | |
| 2023-06-30 | 11 | $1.0B | 0 | |
| 2023-03-31 | 11 | $781.9M | 0 | |
| 2022-12-31 | 11 | $840.2M | 0 | |
| 2022-09-30 | 11 | $884.8M | 0 | |
| 2022-06-30 | 11 | $993.5M | 0 | |
| 2022-03-31 | 11 | $1.1B | 0 | |
| 2021-12-31 | 11 | $1.2B | 0 | |
| 2021-09-30 | 10 | $1.3B | 0 | |
| 2021-06-30 | 14 | $1.3B | 25 | |
| 2021-03-31 | 14 | $1.0B | 47 | |
| 2020-12-31 | 12 | $979.8M | 31 | |
| 2020-09-30 | 11 | $849.4M | 19 | |
| 2020-06-30 | 12 | $898.9M | 44 | |
| 2020-03-31 | 12 | $783.8M | 55 | |
| 2019-12-31 | 13 | $1.2B | 61 | |
| 2019-09-30 | 12 | $797.9M | 16 | |
| 2019-06-30 | 13 | $802.2M | 30 | |
| 2019-03-31 | 11 | $664.3M | 45 | |
| 2018-12-31 | 10 | $451.2M | 25 | |
| 2018-09-30 | 9 | $453.3M | 28 | |
| 2018-06-30 | 10 | $498.8M | 15 | |
| 2018-03-31 | 11 | $432.1M | 54 | |
| 2017-12-31 | 11 | $390.7M | 67 | |
| 2017-09-30 | 9 | $324.0M | 13 | |
| 2017-06-30 | 8 | $299.6M | 48 | |
| 2017-03-31 | 11 | $253.1M | 71 | |
| 2016-12-31 | 11 | $363.1M | 34 | |
| 2016-09-30 | 14 | $434.2M | 51 | |
| 2016-06-30 | 15 | $352.3M | 49 | |
| 2016-03-31 | 16 | $453.8M | 22 | |
| 2015-12-31 | 17 | $514.4M | 44 | |
| 2015-09-30 | 18 | $404.9M | 36 | |
| 2015-06-30 | 16 | $434.6M | 18 | |
| 2015-03-31 | 17 | $474.1M | 69 | |
| 2014-12-31 | 16 | $282.5M | 39 | |
| 2014-09-30 | 14 | $258.9M | 42 | |
| 2014-06-30 | 15 | $294.1M | 28 | |
| 2014-03-31 | 15 | $290.4M | 43 | |
| 2013-12-31 | 12 | $267.0M | 0 |
Sarissa Capital Management LP's most significant position changes for 2026-03-31: Trim: Neurocrine Biosciences INC (NBIX) — shares -61.56%; Trim: Innoviva INC (INVA) — shares -24.33%; Trim: Ironwood Pharmaceuticals INC (IRWD) — shares -42.28%; Trim: Lantheus Holdings INC (LNTH) — shares -8.01%; Trim: Cytokinetics INC (CYTK) — shares -42.32%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INVA | Innoviva INC | +6.3% | -24.33% | Trim |
| 2 | AMRN | Amarin CORP PLC -adr | +4.9% | — | Unchanged |
| 3 | LNTH | Lantheus Holdings INC | +2.6% | -8.01% | Trim |
| 4 | REGN | Regeneron Pharmaceuticals | +0.6% | — | Unchanged |
| 5 | BHVN | Biohaven Ltd. | +0.4% | +9.74% | Add |
| 6 | VOR | Vor Biopharma INC | +0.1% | — | Unchanged |
| 7 | CYTK | Cytokinetics INC | -1.7% | -42.32% | Trim |
| 8 | IRWD | Ironwood Pharmaceuticals INC | -3.6% | -42.28% | Trim |
| 9 | NBIX | Neurocrine Biosciences INC | -9.6% | -61.56% | Trim |